Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

October 20, 2021

Meghan Thompson, MD, discusses the safety profile of pirtobrutinib in patients with Richter transformation.

October 18, 2021

Dr. Ilson discusses treatment sequencing for patients with gastric and gastroesophageal junction cancer, the integration of immunotherapy into the frontline setting, and key ongoing studies in the field.

October 15, 2021

A single, high priming dose of tremelimumab plus durvalumab resulted in a statistically significant and clinically meaningful improvement in overall survival vs sorafenib when used in the frontline treatment of patients with unresectable hepatocellular carcinoma who had not previously received systemic therapy and were not eligible for localized treatment.

October 14, 2021

The initiation of the phase 3 ENHANCE trial looks to build on the generally early response to azacitidine with the addition of magrolimab, a first-in-class monoclonal antibody, for patients with intermediate-, high-, and very high–risk myelodysplastic syndrome.

October 13, 2021

Bob T. Li, MD, PhD, MPH, discusses the limitations of the phase 3 IMpower010 trial in resected stage IB to IIIA non–small cell lung cancer.

October 12, 2021

Raajit K. Rampal, MD, PhD, discusses the importance of risk stratification in myelofibrosis.

October 06, 2021

Robert J. Motzer, MD, spoke about the “exceptional” efficacy of the combination and how it fits into the evolving RCC treatment landscape.

September 28, 2021

While overall cancer cases are declining, they are on the rise in older adolescents and young adults.

September 27, 2021

Patients with relapsed/refractory multiple myeloma, particularly those who have failed a prior BCMA–targeted therapy, represent a population with an unmet need for effective treatment options. Investigators are hoping to help fill this void with the initiation of the phase 2 MagnetisMM-3 study.

September 24, 2021

Bob T. Li, MD, PhD, MPH, discusses the results of the phase 2 DESTINY-Lung01 trial in HER2-positive metastatic non–small cell lung cancer.

September 24, 2021

Yelena Y. Janjigian, MD, further discusses the clinical significance of the FDA approval of nivolumab plus chemotherapy in the frontline treatment of patients with gastric cancer.

September 21, 2021

Meghan Thompson, MD, discusses the results of the phase 1/2 BRUIN study in patients with Richter transformation.

September 20, 2021

The triplet combination of umbralisib, ublituximab, and pembrolizumab demonstrated durable responses with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation.

September 19, 2021

The frontline combination of nivolumab and chemotherapy upheld its improvement in progression-free and overall survival vs chemotherapy alone with longer follow-up of patients with advanced gastric, gastroesophageal junction, or esophageal cancer, according to data from the phase 3 CheckMate-649 trial.

September 16, 2021

Chau T. Dang, MD, discusses the rationale of the phase 2 BERENICE trial in early-stage HER2-positive breast cancer.

September 15, 2021

As part of a global consensus meeting, experts from several disciplines convened to define evidence-based guidelines for the treatment of patients with primary and metastatic epithelioid hemangioendothelioma with locoregional and systemic therapies, as well as palliative care.

September 07, 2021

The combination of pembrolizumab and lenvatinib led to a statistically significant improvement in progression-free survival and overall survival in patients with mismatch repair deficient advanced endometrial cancer following platinum-based chemotherapy.

September 02, 2021

Raajit K. Rampal, MD, PhD, discusses the importance of genomic testing in myelofibrosis.

September 01, 2021

More tailored selection processes, which have placed a greater emphasis on patient-specific characteristics, such as risk and genomic status, and made possible with a growing number of treatment options, have led to optimized therapeutic decisions for patients with hematologic malignancies.

September 01, 2021

The autologous CAR T-cell therapy P-PSMA-101 elicited robust antitumor responses in patients with metastatic castration-resistant prostate cancer, according to preliminary findings from the phase 1 P-PSMA-101-001 trial that were virtually presented during the 6th Annual CAR-TCR Summit.